

## Regimen Reference Order – LEUK – decitabine

ARIA: LEUK - [decitabine]

Planned Course: Every 28 days until disease progression or unacceptable toxicity

Indication for Use: Acute Myeloid Leukemia Relapsed/Refractory

CVAD: At Provider's Discretion

Alert: Special Access Programme (SAP) medication

### Proceed with treatment if:

- Serum creatinine equal to or less than 177 umol/L
- ALT or total bilirubin equal to or less than 2 times upper limit of normal
  - ❖ Contact Physician if parameters not met

Proceed regardless of CBC

## SEQUENCE OF MEDICATION ADMINISTRATION

### Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

### Treatment Regimen – LEUK – decitabine

Drug	Dose	CCMB Administration Guideline
Establish primary solution 500 mL of: normal saline		
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy on <b>Days 1 to 5</b>
dexamethasone	8 mg	Orally 30 minutes pre-chemotherapy on <b>Days 1 to 5</b>
decitabine	20 mg/m <sup>2</sup>	IV in normal saline 100 mL over 1 hour on <b>Days 1 to 5</b> <i>*Alert: A refrigerated diluent bag must be used to compound decitabine. Final compounded product must be refrigerated until administration</i> <i>Concentration dependent drug. Pharmacy will adjust diluent volume to ensure drug stability</i>

Flush after each medication

- 50 mL over 6 minutes (500 mL/hr)

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

## REQUIRED MONITORING

All Cycles

- CBC, biochemistry, serum creatinine, urea, AST, ALT and total bilirubin as per Physician Orders

**Recommended Support Medications**

<b>Drug</b>	<b>Dose</b>	<b>CCMB Administration Guideline</b>
metoclopramide	10 – 20 mg	Orally every 4 – 6 hours as needed for nausea and vomiting

**DISCHARGE INSTRUCTIONS**

- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

**ADDITIONAL INFORMATION**

- Administration site restrictions are in place for decitabine due to short drug stability. decitabine can only be administered at a site in which a pharmacy is on site